alexa An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
Oncology

Oncology

Journal of Oncology Medicine & Practice

Author(s): Liu PY, Alberts DS, Monk BJ, Brady M, Moon J,

Abstract Share this page

Abstract PURPOSE: For ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy, we tested the predictive value of the following early signal of progressive disease (EPD) criterion based on serum CA-125: for patients with CA-125 nadir or= 20 U/mL serves as an early signal of CA-125 progression; for patients with nadir more than 10 U/mL, a value >or= 2x nadir that is confirmed predicts progression. PATIENTS AND METHODS The EPD criterion was tested on Southwest Oncology Group trial 9701/Gynecologic Oncology Group trial 178 patients (n = 288) and compared with Gynecologic Cancer Intergroup criterion. RESULTS: For 204 patients with known progressive disease, the progression date was predated by EPD by
  • DOI: 10.1200/JCO.2006.09.4540
  • This article was published in J Clin Oncol and referenced in Journal of Oncology Medicine & Practice

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

     
    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords